In 1993-1995, tuberculosis morbidity increased from 37.8 per 100,000 inhabitants to 55.7. The increase was due chiefly due to incidence rates among urban dwellers. In the same period, tuberculosis mortality rose from 10.2 to 55.7 per 100,000. Tuberculosis control strategy has been revised under the conditions of the increasing spread of tuberculosis infections and the Central Research Institute of the Russian Academy of Medical Sciences jointly with the WHO Global Programme Department has developed the programme "Detection of Patients Isolating Mycobacterium tuberculosis by the ??Tsil-Nilsen method and Their Short-Term Chemotherapy". Analyzing the preliminary data available during 2 quarters (Quarter IV, 1995, and Quarter I, 1996) indicated its adequate efficiency.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Tuberculosis in the US Kidney Failure Population.
J Am Soc Nephrol
January 2025
Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia.
Background: People with chronic kidney disease (CKD) have a higher risk for progression to tuberculosis disease following infection with Mycobacterium tuberculosis. We produced a nationwide incidence estimate and description of tuberculosis among people with kidney failure.
Methods: We completed a cross-sectional descriptive analysis of people with a reported case of tuberculosis in the United States between 2010 and 2021.
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer.
Oncologist
January 2025
Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Thoracic Oncology, 1066 CX Amsterdam, The Netherlands.
Introduction: We describe the safety of sotorasib monotherapy in patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) and discuss practical recommendations for managing key risks.
Methods: Incidence rates of treatment-related adverse events (TRAEs) were pooled from 4 clinical trials: CodeBreaK 100 (NCT03600883), CodeBreaK 101 (NCT04185883), CodeBreaK 105 (NCT04380753), and CodeBreaK 200 (NCT04303780) and graded according to CTCAE v5.0.
Allergic Rhinitis and its Impact on Asthma (ARIA) Classes in MASK-air Users.
J Investig Allergol Clin Immunol
January 2025
MASK-air, Montpellier, France.
Background And Objectives: The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines classify rhinitis as "intermittent" or "persistent" and "mild" or "moderate-severe". To assess ARIA classes in a real-world study in terms of phenotypic differences and their association with asthma.
Methods: We performed a cross-sectional real-world study based on users of the MASK-air® app who reported data for at least 3 different months.
Etiological Insights and the Role of Individual Factors in Infectious Spondylodiscitis.
Infect Dis Rep
January 2025
Department of Physiology, The "Carol Davila" University of Medicine and Pharmacy, 8 Eroii Sanitari Boulevard, 050474 Bucharest, Romania.
Spondylodiscitis can be caused by various microorganisms and has shown a continuous rise in incidence and mortality. The purpose of our study was to analyze the demographic and laboratory data, as well as comorbidities of patients that were surgically treated for spondylodiscitis in our hospital. The causative pathogens involved in the etiology of spinal infections were also assessed.
View Article and Find Full Text PDFSystematic Review on 1,2,3-Oxadiazoles, 1,2,4-Oxadiazoles, and 1,2,5-Oxadiazoles in the Antimycobacterial Drug Discovery.
ChemMedChem
January 2025
Charles University Faculty of Pharmacy in Hradec Kralove: Univerzita Karlova Farmaceuticka fakulta v Hradci Kralove, Dept. of pharmaceutical chemistry and pharmaceutical analysis, Ak. Heyrovskeho 1203/8, 50003, Hradec Kralove, Czech Republic, CZECHIA.
Tuberculosis remains a leading global health threat, exacerbated by the emergence of multi-drug-resistant strains. The search for novel therapeutic agents is critical in addressing this challenge. This review systematically summarizes the potential of oxadiazole derivatives as promising candidates in antimycobacterial drug discovery.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!